CANSINO BIOLOGICS IN

6185
End-of-day quote. End-of-day quote  - 08/05
254.8HKD -1.39%
Income Statement Evolution
Annual Income Statement Data
Fiscal Period: December 2019 2020
Net sales1 -228
EBITDA1 -178-145
Operating profit (EBIT)1 -200-161
Operating Margin --70,6%
Pre-Tax Profit (EBT)1 -157-103
Net income1 -157-91,2
Net margin --39,9%
EPS2 -0,70-0,62
Dividend per Share2 --
Last update 03/27/202005/24/2020
1 CNY in Million
2 CNY
Estimates
Finances - Leverage
Fiscal Period: December 2019 2020
Net Debt1 -31,6
Net Cash position1 588-
Leverage (Debt / EBITDA) 3,31x-0,22x
Free Cash Flow1 -280-56,0
ROE (Net Profit / Equities) -15,9%-10,1%
Shareholders' equity1 986907
ROA (Net Profit / Asset) -12,2%-11,0%
Assets1 1 290829
Book Value Per Share2 7,235,97
Cash Flow per Share2 -0,84-0,80
Capex1 11061,3
Capex / Sales -26,9%
Last update 03/27/202008/04/2020
1 CNY in Million
2 CNY
Estimates
Balance Sheet Analysis
Financial Ratios
Size 2020e 2021e
Capitalization 50 768 M CNY -
Entreprise Value (EV) 50 800 M CNY 49 574 M CNY
Valuation 2020e 2021e
P/E ratio (Price / EPS) -368x 304x
Capitalization / Revenue 222x 71,1x
EV / Revenue 222x 71,1x
EV / EBITDA -351x 78,1x
Yield (DPS / Price) - -
Price to book (Price / BVPS) 38,2x 21,9x
Profitability 2020e 2021e
Operating Margin (EBIT / Sales) -70,6% 20,3%
Operating Leverage (Delta EBIT / Delta Sales) - 0,89x
Net Margin (Net Profit / Revenue) -39,9% 24,2%
ROA (Net Profit / Asset) -11,0% 3,10%
ROE (Net Profit / Equities) -10,1% 6,78%
Rate of Dividend - -
Balance Sheet Analysis 2020e 2021e
CAPEX / Sales   26,9% 8,65%
Cash Flow / Sales -78,0% -0,22%
Capital Intensity (Assets / Sales) 3,63x 7,81x
Financial Leverage (Net Debt / EBITDA) -0,22x -
Price Earning Ratio
EPS & Dividend